The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer.

Furthermore, patients without peritoneal metastasis demonstrated better PFS (6.1 months versus 5.0 months) and OS (not reached versus 14.6 months) compared to those with peritoneal metastasis, though these differences did not reach statistical significance.

also in 111,027 other papers

Median PFS and OS were 6.1 months and 14.6 months, respectively; patients with CPS ≥ 5 showed a trend towards better PFS and OS than those with CPS < 5.

also in 53,322 other papers

Similarly, our cohort demonstrated not reached median PFS and OS in patients with CPS ≥ 5, suggesting borderline significant improvements compared to CPS < 5 patients.

also in 11,409 other papers